Daré Bioscience closes initial tranche of Reg A offering at $5/unit; issues 5,090 units

Dare Bioscience, Inc.

Initial closing on Jan 27, 2026: issued 5,090 Units (each 1 share Series A Preferred + 2 warrants) for $25,450 gross proceeds.
Series A Preferred convertible at $2.50/share, no dividends, liquidation preference $5/share, senior to common stock.
Investor warrants exercisable at $4.00/share for 36 months; Agent warrants at $6.25/unit, subject to 180-day lock-up.
Company can call preferred after 3 years at lesser of stated value + 8% annual or 200% of stated value.
Forced conversion triggers: change of control, stock price ≥$4.50 for 10 of 30 days, or firm IPO ≥$15M at ≥$4.50.

item 3.02 item 8.01 item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Dare Bioscience, Inc.: Filed Certificate of Designation designating 4,999,620 shares as Series A Convertible Preferred Stock, establishing powers, preferences, and rights (effective 2026-01-23).

Change: charter amendment
Effective: 2026-01-23

Exact text from the filing

On January 23, 2026, in anticipation of the initial closing of the Offering (as defined below), Daré Bioscience, Inc. (“Daré” “we,” “us,” or “our”) filed a Certificate of Designation of Series A Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, which became effective upon filing.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-004245

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.